Cambridge, UK - 6th December 2016
Nuformix announces today that the US PTO has granted Nuformix’s NXP002 patent. Nuformix is pursuing global patent coverage for its NXP002 asset, which offers great promise for use in multiple reprofiled indications.
Nuformix Chief Executive Officer Dr Dan Gooding said: “NXP002 represents Nuformix’s fifth success in securing substance-of- matter patent protection for a novel cocrystal drug form in the US. The USPTO decision demonstrates the strength of Nuformix’s US IP strategy with a well-established precedent in place for future filings. Nuformix has established a thorough understanding of the data required to secure broad patent protection in the US and navigate the examination process for what remains a relatively novel technology. We look forward securing further grants for additional key territories.”